Annual revenue fell from KRW 9.12 billion in 2022 to KRW 4.9 billion in 2023, a 46.3% decline, then rose to KRW 6.79 billion in 2024 (up 38.7%) and KRW 12.3 billion in 2025 (up 80.9%).
Revenue has grown for two consecutive years from 2024 through 2025, with 2025 the largest year and 2023 the smallest in the 2022–2025 period. The company attributes the 2025 increase to about KRW 4.9 billion from the Petraon Care Lab business and a roughly KRW 350 million rise at subsidiary Protium Science.
Operating loss was KRW 25.6 billion in 2022, KRW 27.8 billion in 2023 (wider), KRW 18.7 billion in 2024 (narrower) and KRW 16.1 billion in 2025 (narrower), a four-year run of losses. Operating margin moved from -281.2% in 2022 to -568.1% in 2023, then improved to -275.3% in 2024 and -131.4% in 2025.
Net loss attributable to controlling shareholders was KRW 31.4 billion in 2022, KRW 19 billion in 2023, KRW 23.5 billion in 2024 and KRW 18.8 billion in 2025.
Quarterly operating losses were KRW 4.52 billion in Q3 2025, KRW 2.79 billion in Q4 2025, KRW 4.54 billion in Q1 2026, KRW 4.24 billion in Q2 2026 and KRW 3.17 billion in Q3 2026, five consecutive loss quarters.
Quarterly revenue dipped to KRW 2.95 billion in Q1 2026, rebounded to KRW 4.48 billion in Q2 and was KRW 3.81 billion in Q3, up 22.0% from a year earlier.
The debt ratio rose from 54.5% in 2022 to 161.1% in 2025, with total liabilities of KRW 60.8 billion and total equity of KRW 37.7 billion at year-end 2025, of which controlling shareholders hold KRW 40.8 billion. Operating cash flow was negative every year from 2022 to 2025.